Regardless of the sequential decrease in Current Liabilities, during the second quarter 2024, Quick Ratio deteriorated to 0.01 a new company low.

Within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Seelos Therapeutics Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 2830 to 4539.

Explain Quick Ratio?
How much Cash & cash equivalents SEEL�s has?
What are SEEL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SEEL Quick Ratio	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2
Y / Y Current Liabilities Change	-45.62 %	-6.34 %	54.73 %	69.13 %	312.16 %
Y / Y Cash & cash equivalent Change	-94.97 %	-96.27 %	-80.71 %	-91.53 %	-85.84 %
Quick Ratio MRQ	0.01	0.01	0.08	0.07	0.1
SEEL's Total Ranking	# 4539	# 2830	# 3092	# 3717	# 2812
Seq. Current Liabilities Change	-16.89 %	-5.68 %	10.19 %	-37.04 %	43.14 %
Seq. Cash & cash equivalent Change	-43.89 %	-82.51 %	15.94 %	-55.78 %	-58.44 %

Quick Ratio second quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 476
Healthcare Sector	# 993
Overall Market	# 4539

Quick Ratio Statistics
High	Average	Low
11.48	2.43	0.01
(Jun 30 2021)		(Jun 30 2024)

Financial Statements
Seelos Therapeutics Inc 's Current Liabilities	$ 31 Millions	Visit SEEL's Balance sheet
Seelos Therapeutics Inc 's Cash & cash equivalent	$ 0 Millions	Visit SEEL's Balance sheet
Source of SEEL's Sales		Visit SEEL's Sales by Geography

Cumulative Seelos Therapeutics Inc 's Quick Ratio

SEEL's Quick Ratio for the trailling 12 Months

SEEL Quick Ratio	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	0.09 %	69.01 %	143.06 %	194.56 %	255.28 %
Y / Y Cash & cash equivalent TTM Growth	-90.3 %	-88.21 %	-82.91 %	-82.09 %	-74.5 %
Quick Ratio TTM	0.05	0.07	0.15	0.24	0.47
Total Ranking TTM	# 3662	# 2902	# 3663	# 3821	# 3605
Seq. Current Liabilities TTM Growth	-15.32 %	-1.46 %	8.84 %	10.22 %	42.99 %
Seq. Cash & cash equivalent TTM Growth	-46.45 %	-53.12 %	-32.98 %	-42.35 %	-34.93 %

Quick ratio ranking by company, industry and sector >> Back to SEEL Financial Strength Comparisons >> Go to Compare SEEL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SEEL's Current Liabilities to $30.51 millions, cumulative Quick Ratio to 0.05 below the SEEL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 463 other companies have achieved higher Quick Ratio than Seelos Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 2902 to 3662.

Explain Quick Ratio?
How much Cash & cash equivalents SEEL�s has?
What are SEEL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 464
Healthcare Sector	# 972
Within the Market	# 3662

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.94	2.5	0.05
(Mar 31 2022)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2024 MRQ Cash & cash equivalent	Jun 30 2024 MRQ Current Liabilities
Pmgc Holdings Inc	0.02	$ 0.046 Millions	$ 1.935 Millions
Emmaus Life Sciences Inc	0.02	$ 1.525 Millions	$ 64.025 Millions
Actuate Therapeutics Inc	0.02	$ 0.352 Millions	$ 20.478 Millions
Cell Source Inc	0.02	$ 0.091 Millions	$ 5.418 Millions
Accustem Sciences Inc	0.02	$ 0.046 Millions	$ 3.024 Millions
Polomar Health Services, Inc.	0.01	$ 0.000 Millions	$ 0.023 Millions
Zyversa Therapeutics Inc	0.01	$ 0.119 Millions	$ 9.995 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.008 Millions	$ 0.637 Millions
Regen Biopharma Inc	0.01	$ 0.062 Millions	$ 5.328 Millions
Nexien Biopharma Inc	0.01	$ 0.004 Millions	$ 0.365 Millions
Bioxytran Inc	0.01	$ 0.014 Millions	$ 1.229 Millions
Seelos Therapeutics inc	0.01	$ 0.294 Millions	$ 30.514 Millions
Lunai Bioworks Inc	0.01	$ 0.220 Millions	$ 30.310 Millions
Celularity Inc	0.01	$ 0.467 Millions	$ 67.900 Millions
Gelteq Limited	0.01	$ 0.016 Millions	$ 2.581 Millions
Propanc Biopharma Inc	0.01	$ 0.021 Millions	$ 3.793 Millions
Reshape Lifesciences Inc	0.00	$ 0.012 Millions	$ 2.421 Millions
Oncotelic Therapeutics Inc	0.00	$ 0.072 Millions	$ 16.204 Millions
Aditxt Inc	0.00	$ 0.091 Millions	$ 20.566 Millions
Provectus Biopharmaceuticals Inc	0.00	$ 0.030 Millions	$ 8.369 Millions
Panbela Therapeutics Inc	0.00	$ 0.059 Millions	$ 16.788 Millions
Os Therapies Incorporated	0.00	$ 0.095 Millions	$ 28.306 Millions
Orgenesis Inc	0.00	$ 0.077 Millions	$ 31.700 Millions
Semnur Pharmaceuticals Inc	0.00	$ 0.014 Millions	$ 6.594 Millions

Date modified: 2026-09-26T07:29:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.